Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 8/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8552304 | 0.84 | CA9 (0.39) | HDAC1 | |
| SCHEMBL6641956 | 0.72 | HTR1F (0.81) | HTR1FNPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL5906460 | 0.71 | HTR1F (0.59) | HTR1FNPC1RAB9AHDAC1ALDH1A1 | |
| Oxalic Acid SCHEMBL6648004 | 0.64 | HTR1F (0.51) | HTR1FNPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL2570298 | 0.59 | KMT2A (0.70) | NPC1RAB9AKMT2AMEN1ATM | |
| Oxalic Acid SCHEMBL6806129 | 0.58 | HTR1F (0.63) | HTR1FNPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL38661985 | 0.58 | BRD4 (0.50) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL6641025 | 0.58 | HTR1F (0.71) | HTR1F | |
| SCHEMBL25676392 | 0.57 | KMT2A (0.70) | NPC1RAB9AKMT2AMEN1ATM | |
| SCHEMBL26785568 | 0.56 | DEGS1 (0.68) | NPC1RAB9AALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | disclosed |
| US-6696439-B1 | HETEROCYCLIC IMINES SUCH AS 2-METHYL-3-(2-(N',N'-DIETHYLAMINO) ETHYL)-5-(4-PROPANESULFONYLBENZAMIDE)FURO(3,2-B)PYRIDINE, HYDROCHLORIDE, USED AS SEROTONIN RECEPTOR ANTAGONISTS FOR PROPHYLAXIS OF HEADACHES | ELI LILLY AND COMPANY | 2004-02-24 | — | — | US | disclosed |
| EP-1155020-B1 | FURO[3,2-B]PYRIDINES AS 5-HT1F AGONISTS | LILLY CO ELI (US) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | HTR1F, HTR1A, HTR1E | HTR1F 1/4885NPC1 840/4885RAB9A 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.